WhatsUp, here : HQNT (.69/.71) --- EPS of 20 cents (PE of 3.5) or more is expected in the next 12-16 months based on the LabQuotient product alone. (see PR and math below)
(this is very unlike most all microcaps -- virtually debt-free, extremely experienced management with much larger companies like Freddie Mac, profitable last 2 years per filings, real products)
High Margin Niche
H-Quotient, Inc., formed in 1993, creates and produces state-of-the art computer software systems that collect and act upon real-time information critical to improving the delivery of healthcare
I verified the potential (i.e. what they see as a likely minimum) with Mr. Cohn, CEO and former West Point grad, late yesterday (see below). Remember that I like this stock based on high powered new management and new product release (see below) and fundamentals, especially future potential.
Why did the stock drop so badly from $7?
The stock tanked from $7 in 2000 with all microcaps and the economy (see partly why below) and was forgotten about like many, but has remained profitable and is now getting recognized again. Only 25M shares O/S, so EPS can ramp if new product is successful as expected based on pre-orders. (see PR below)
The other encouraging thing is that Briefing reported yesterday that Small and Micro Caps are easily outperforming the Naz this year. Money Flow and OBV has been very good in this stock even as it has treaded water a bit the last few weeks and slowly risen. I would check this for yourself as well at bigchart.com or your favorite charting service.
bigcharts.marketwatch.com.
MORE INFO
** Website: hquotient.com
** Stock has been to about $7.00 per share in the past 2 years and has been profitable in that time (all should check the SEC filings). I believe they made 13 cents EPS in 2000-2001.
** Stock crashed, according to the Company, along with most all microcap and tech stocks in mid-2000 and only recently recovered. The other reason was a large shareholder that dumped 3M shares onto the market over a 6 month period. That selling is done, new Management is in place, including a respected scientist, Dr. Laipply at Quest Diagnostics and a former Senior VP at Freddie Mac to launch LaqQuotient, their new product (see below)
** The PR below mentions a new product (LabQuotient) that based on pre-orders and reviews, leads the company to figure that $5M "Net" or about 20 cents EPS will flow to the bottom line on this one product alone ($5M divided by 25M shares outstanding = 20 cents EPS just)
RECENT NEWS
H-Quotient, Inc., Announces LabQuotient; $5 Million Net Projected
VIENNA, Va., Mar 25, 2002 /PRNewswire-FirstCall via COMTEX/ -- H-Quotient, Inc., (OTC Bulletin Board: HQNT chart, msgs) and Dr. Thomas C. Laipply, MD, FCAP, FIAP, Director of Molecular Tissue Pathology, Nichols Institute at Quest Diagnostics announced LabQuotient, a relational database for improving and monitoring medical test ordering. The product is expected to be ready for market this summer.
Pre-production orders have been received. Further details will be announced in a subsequent release.
H-Quotient, Inc., is projected to earn net income of $5 million in the product's first year. All income will be recurring and is expected to grow substantially because the universe for this revolutionary product includes clinical doctors, dentists, veterinarians, emergency rooms, urgent care centers, insurance companies, HMOs, hospital quality assurance personnel, commercial laboratories, and pharmaceutical-drug companies.
Dr. Laipply said, "LabQuotient is a new and innovative software product that will significantly improve medical diagnosis and treatment while reducing the ongoing problem of inappropriate and unnecessary testing. It fills the diagnosis/testing gap that has dramatically widened over the last decade."
H-Quotient Vice President of Operations Laurance T. Burden said, "LabQuotient fills a critical need and we are uniquely positioned to deliver it with our advanced technology."
CEO and President Douglas A. Cohn said, "This is quite simply the most significant event in H-Quotient's history, but more important, it will soon have a positive impact on patient care and medical costs."
This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.
For more information visit the H-Quotient web site at hquotient.com .
MAKE YOUR OPINION COUNT - Click Here
tbutton.prnewswire.com
Source: H-Quotient, Inc.
Contact:
H-Quotient, Inc., +1-703-821-3434
URL: hquotient.com
As always do your own DD. To be totally upfront and honest,
I am receiving some one year restricted stock, meaning I cannot sell any of it for one year and have not even received it. I bought some personally between 60 and 70 cents recently for my own account. The CEO, Doug Cohn, asked me to help try to give his company exposure to longer term shareholders after hearing about the thread's award in Forbes and commendations about my integrity. He feels the Company is highly undervalued based on current and future fundamentals, something each investor must decide for themselves, of course. Information I post is based on information from the Company and thier representatives and from SEC filings and PR's. I believe all information I post to be accurate but cannot guarantee it, of course.
Please visit their website for further Due Diligence and see their recent PR's and filings for more information on their new product, management, etc. PM me with any questions or call me on my cell at (206) 310-9898 or call Mr. Cohn @ (703) 821-3431 and mention me (Bob Krause -"Dave Gore" is my pen name on SI as most of you know if you have known me for several years or have visited my photo website at naturescapes-gallery.com |
